• ≥18 years of age;

• Histologically documented CD20+ mature B-cell neoplasm

  • Large B-cell lymphoma
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Chronic lymphocytic leukemia
  • Small lymphocytic lymphoma

• Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy;

• ECOG performance status of ≤ 2 (< 2 in EU countries).

The above is a summary, other inclusion criteria details may apply.

• Any neoplasm histology not specified in the IC section;
• Active CNS involvement in lymphoma;
• CNS pathology including but not limited to any history of seizure disorder/epilepsy;
• Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy;
• History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS;
• Active and uncontrolled infections;
• Unresolved AEs ≥2 Grade due to prior anticancer therapies, with some exceptions

The above is a summary, other exclusion criteria details may apply.